PositoAI
a positivity index
Home Explore Actions Flows Indices News Watchlist Compare PosiDemy Screeners Insights
PosiFunda · Fundamentals

JINS HOLDINGS Inc.

PosiFunda Ratios Only on PositoAI

PositoAI's own ratios from JINS HOLDINGS Inc.'s yearly results (2022–2025), compared with Healthcare companies in Japan. Tap ? on any ratio for what it means.

What stands out

  • Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 92% of Healthcare companies in Japan.

Where ¥100 of sales goes

¥88Operating costs¥0.2Interest¥8.6Net profit¥2.2Paid as dividends

Latest year (Aug 2025). Taxes and other income are not shown, so the parts need not add up to 100.

Cash quality

Profit Cash Ratio

¥187

Over the last 3 years, every ¥100 of reported profit came with ¥187 of operating cash.

Higher than 80% of Healthcare companies in Japan.

Self-Funding Ratio

2.4×

Over the last 3 years its own operating cash covered its investment spending (capex) 2.4 times.

Higher than 66% of Healthcare companies in Japan.

Cash Locked Ratio

¥0

For every ¥100 of sales, ¥0 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ¥3 tied up three years earlier.

Less money tied up than 83% of Healthcare companies in Japan.

Growth quality

Steadiness Ratio

3/3 · 3/3

Sales and profit both grew in each of the last 3 years.

Steadier than 92% of Healthcare companies in Japan.

Growth Efficiency Ratio

¥25

Sales grew 45% in 3 years; of every extra ¥100 of sales, ¥25 became extra profit.

Higher than 77% of Healthcare companies in Japan.

Asset Productivity Ratio

+45% / +6%

In 3 years sales changed by +45% while total assets changed by +6%. Sales grew faster than assets.

Balance-sheet strength

Debt Due Cover Ratio

1.9×

Debt due within a year is covered 1.9 times by its yearly operating cash.

Higher than 68% of Healthcare companies in Japan.

Cash Cushion Ratio

+4%

Cash, after subtracting all debt, equals 4% of its market value (net cash).

Higher than 50% of Healthcare companies in Japan.

Tangible Assets Ratio

90%

Of every ¥100 the company owns, ¥90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.

Less tangible than 71% of Healthcare companies in Japan.

Tangible Net Worth Ratio

82%

Of every ¥100 of net worth, ¥82 is tangible; the rest is goodwill and other intangibles, often from buying other companies.

Less tangible than 70% of Healthcare companies in Japan.

Shareholders

Shareholder Slice Ratio

0%

Share count was unchanged over the last 3 years. Dividends paid equalled 24% of profit over the same period.

Standard fundamentals

P/E, P/B, ROE, debt, growth and more (14)

JINS HOLDINGS Inc. owes ¥0.44 for every ¥1 it owns. Net profit rose 78% in the year to Aug 2025, and grew 123% a year on average over 3 years.

Compared with Healthcare companies in Japan · latest annual results Aug 2025.

P/E ratio

18.0

Investors pay ¥18.0 for every ¥1 of JINS HOLDINGS Inc.'s yearly profit, higher than 60% of Healthcare companies in Japan.

P/B ratio

4.11

The share price is 4.11 times JINS HOLDINGS Inc.'s book value per share, higher than 83% of Healthcare companies in Japan.

Market cap

¥139.2 B

The total market value of all of JINS HOLDINGS Inc.'s shares at today's price (share price × number of shares), larger than 77% of Healthcare companies in Japan. PosiCap size class: Mini Cap.

Net worth (book value)

¥33.9 B

What JINS HOLDINGS Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (28 Feb 2026).

Book value per share

¥1,451

Net worth divided by the number of shares. The share price of ¥5,960 is 4.1 times this, which is the P/B above.

Return on equity (ROE)

22.6%

JINS HOLDINGS Inc. earned 22.6% on its shareholders' money over the last year, higher than 93% of Healthcare companies in Japan.

Owes vs Owns

0.44×

JINS HOLDINGS Inc. owes ¥0.44 for every ¥1 it owns (low), higher than 54% of Healthcare companies in Japan.

Dividend yield

2.29%

JINS HOLDINGS Inc. pays 2.29% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in Japan.

Revenue growth

+17%

Revenue rose 17% in the year to Aug 2025, and grew 13% a year on average over 3 years.

Profit growth

+78%

Net profit rose 78% in the year to Aug 2025, and grew 123% a year on average over 3 years.

Profit margin

8.6%

JINS HOLDINGS Inc. keeps ¥9 of every ¥100 of revenue as net profit.

Cash quality

1.3×

Cash from JINS HOLDINGS Inc.'s business was 1.3× its reported profit in the year to Aug 2025 — its profit turned into cash.

Interest cover

78.0×

JINS HOLDINGS Inc.'s operating profit covered its interest costs 78.0 times in the year to Aug 2025.

Cash vs debt

Net cash

JINS HOLDINGS Inc. held ¥6.2 B more cash than debt (net cash) at Aug 2025.

Questions

What is JINS HOLDINGS Inc.'s P/E ratio?

Investors pay ¥18.0 for every ¥1 of JINS HOLDINGS Inc.'s yearly profit, higher than 60% of Healthcare companies in Japan.

How is P/B calculated on PositoAI?

P/B is market cap divided by net worth from the latest balance sheet. For JINS HOLDINGS Inc.: ¥139.2 B ÷ ¥33.9 B (28 Feb 2026) = 4.1.

What is JINS HOLDINGS Inc.'s return on equity?

JINS HOLDINGS Inc. earned 22.6% on its shareholders' money over the last year, higher than 93% of Healthcare companies in Japan.

How much does JINS HOLDINGS Inc. owe compared with what it owns?

JINS HOLDINGS Inc. owes ¥0.44 for every ¥1 it owns (low), higher than 54% of Healthcare companies in Japan.

Does JINS HOLDINGS Inc. pay a dividend?

Yes. JINS HOLDINGS Inc. pays 2.29% of its share price as dividends a year, lower than 62% of dividend-paying Healthcare companies in Japan.

Is JINS HOLDINGS Inc.'s revenue growing?

Revenue rose 17% in the year to Aug 2025, and grew 13% a year on average over 3 years.

Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.